NuPathe acquired by Teva for $144M - Technical.ly Philly

Business

Jan. 22, 2014 7:30 am

NuPathe acquired by Teva for $144M

The publicly-traded NuPathe chose Teva's offer over a competing offer from Chester County-based Endo Health Solutions.

Teva Pharmaceutical Industries, shown here, bought NuPathe for $144 million. Photo by Ronen Zvulun for Reuters.

Malvern-based pharmaceutical company NuPathe was acquired by Israeli company Teva, which also has a regional presence, for $144 million in cash, according to a release. The publicly-traded NuPathe chose Teva’s offer over a competing offer from Chester County-based Endo Health Solutions.

The company makes a migraine painkiller called Zecuity. It was a former Science Center tenant.

NuPathe was backed by Safeguard Scientifics, making that two exits for the venture capital firm in as many months. Other investors include Quaker BioVentures, Benjamin Franklin Technology Partners, Bio Advance and Battelle Ventures. This is a classic Philadelphia technology business story: biomedical innovation developed, commercialized, invested in, gone public and then acquired by a larger pharma company.

Read our 2009 Q&A with former NuPathe CEO Jane Hollingsworth here.

Read more on the Philadelphia Inquirer.

-30-
CONTRIBUTE TO THE
JOURNALISM FUND

Already a contributor? Sign in here
Connect with companies from the Technical.ly community
New call-to-action

Advertisement

Sign-up for daily news updates from Technical.ly Philadelphia

Do NOT follow this link or you will be banned from the site!